Biocryst Pharmaceuticals Inc financial data

Symbol
BCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4505 Emperor Boulevard, Suite 200, Durham, NC
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 314 % -41.8%
Quick Ratio 12.8 % -57.2%
Return On Equity 26.4 % -60.3%
Return On Assets -25.4 % +43.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 207M shares +1.13%
Common Stock, Shares, Outstanding 207M shares +9.12%
Entity Public Float 1.32B USD
Common Stock, Value, Issued 2.07M USD +9.12%
Weighted Average Number of Shares Outstanding, Basic 207M shares +9.1%
Weighted Average Number of Shares Outstanding, Diluted 207M shares +9.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 195M USD -11.1%
Costs and Expenses 453M USD +6.68%
Operating Income (Loss) -40.7M USD +62.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -124M USD +47.1%
Income Tax Expense (Benefit) -308K USD -117%
Net Income (Loss) Attributable to Parent -124M USD +47.6%
Earnings Per Share, Basic -0.61 USD/shares +51.2%
Earnings Per Share, Diluted -0.61 USD/shares +51.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96.8M USD -35.8%
Accounts Receivable, after Allowance for Credit Loss, Current 72.5M USD +35.1%
Inventory, Net 7.56M USD -74.5%
Assets, Current 427M USD -15%
Property, Plant and Equipment, Net 7.42M USD -17.5%
Operating Lease, Right-of-Use Asset 8.34M USD -26.7%
Other Assets, Noncurrent 15.6M USD +36.6%
Assets 491M USD -6.06%
Accounts Payable, Current 13.5M USD +27.6%
Employee-related Liabilities, Current 36.5M USD +65.1%
Accrued Liabilities, Current 104M USD +34.6%
Liabilities, Current 154M USD +69.2%
Operating Lease, Liability, Noncurrent 8.07M USD -19.1%
Liabilities 960M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.29M USD +187%
Retained Earnings (Accumulated Deficit) -1.74B USD -7.65%
Stockholders' Equity Attributable to Parent -469M USD -14%
Liabilities and Equity 491M USD -6.06%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -53.7M USD -13%
Net Cash Provided by (Used in) Financing Activities -1.05M USD -121%
Net Cash Provided by (Used in) Investing Activities 28.8M USD
Common Stock, Shares Authorized 450M shares 0%
Common Stock, Shares, Issued 207M shares +9.12%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -26.3M USD +82.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.99M USD -30.2%
Deferred Tax Assets, Valuation Allowance 437M USD +12.2%
Deferred Tax Assets, Gross 441M USD +12.6%
Operating Lease, Liability 9.11M USD -25.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -122M USD +48%
Lessee, Operating Lease, Liability, to be Paid 15M USD -21.5%
Property, Plant and Equipment, Gross 19.1M USD +5.25%
Operating Lease, Liability, Current 1.05M USD -54%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.68M USD -27.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.92M USD -41.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +10%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.91M USD -14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.59M USD -13.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 14.4M USD +3.74%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.42M USD -7.51%
Operating Lease, Payments 2.02M USD +44%
Additional Paid in Capital 1.27B USD +5.36%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 306K USD -24.4%
Share-based Payment Arrangement, Expense 60.6M USD +40.5%
Interest Expense 101M USD -5.93%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%